Industries
Pharma Outsourcing (CRO)
All research in Pharma Outsourcing (CRO) — 3 reports.
38/100
Fortrea Deep Dive: Global Clinical CRO Repair After the Labcorp Spin-Off
Fortrea is a global CRO spun out of Labcorp in 2023, focused on Phase II-IV clinical operations and clinical pharmacology, with 2025 revenue of $2.723 billion. Its book-to-bill has stayed above 1.1x for three consecutive quarters, but the midpoint of 2026 revenue guidance still implies a decline and gross debt is about 5.6x adjusted EBITDA. Research rating Watch: early order recovery is visible, while revenue decline and high leverage have not yet been resolved.
37/100
ICON plc In-Depth Research
ICON plc (ICLR) is one of the world's leading clinical research outsourcing providers, or CROs. The 2026 accounting restatement confirmed control failures and a one-time $3.9 billion backlog reduction, yet 2025 free cash flow still reached $862 million, putting the company into a valuation reset under a governance discount. Report rating Hold: the valuation already reflects part of the bad news, but governance repair is not yet strong enough to support a Buy rating, with an ideal buy zone of $108 to $116.
49/100
Medpace Holdings Zen Horizon Framework Deep-Dive Research
Medpace Holdings is one of the leading U.S. full-service clinical CROs, focused on small and mid-sized biotech clients, founder-controlled, debt-free, and an exceptional high-ROIC compounder. The core thesis is that business quality remains outstanding, but current valuation, weakening leading indicators, and biotech funding-cycle exposure leave little margin of safety. Research rating Watch: a high-quality compounder worth monitoring, with a better entry point likely below $380 or after book-to-bill recovers above 1.0x.